
Gene therapies’ moment of reckoning
Safety concerns, sceptical patients, hefty price tags and a host of manufacturing challenges have humbled the gene therapy field. Keystone-SDA / Gaetan Bally Listen to the article Listening the article Toggle language selector Select your language …